BRÈVE

sur Theralase Technologies Inc. (isin : CA88337V1004)

Rutherrin® Increases Efficacy of Chemotherapy

TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. announced significant preclinical findings regarding its lead drug formulation, Rutherrin®. The data suggest Rutherrin® can enhance chemotherapy efficacy and reduce multidrug resistance (MDR).

Multidrug resistance is a common issue in cancer treatment, often due to the overexpression of ATP-Binding Cassette (ABC) transporters. These transporters pump chemotherapeutic drugs out of cancer cells, diminishing their effectiveness. Rutherrin® appears to inhibit this efflux, allowing for higher intracellular drug accumulation.

Various chemotherapeutic drugs showed increased retention and cell kill rates when combined with Rutherrin®. Additionally, mouse models demonstrated delayed tumor progression and improved survival rates with Rutherrin® plus Vinblastine.

Dr. Arkady Mandel stated that adding Rutherrin® could maintain or enhance chemotherapy effectiveness by modulating drug efflux. CEO Roger DuMoulin-White highlighted Rutherrin®’s potential to optimize cancer treatments and overcome MDR challenges.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Theralase Technologies Inc.